Catalog No.
DHJ63105
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NPF7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LY-3074828, CAS: 1884201-71-1
Clone ID
Mirikizumab
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab, PMID: 34447766
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark Special Reporting on:• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With Vedolizumab PLUS Meeting Abstract Summaries With Expert Commentary by: Edward V. Loftus Jr, MD Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota, PMID: 31632213
Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease, PMID: 30571147
Anti-interleukin-23 agents for the treatment of ulcerative colitis, PMID: 31760827
Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks, PMID: 33098883
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease, PMID: 33105016
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis, PMID: 32950748
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study, PMID: 30734266
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis, PMID: 31493397
Emerging systemic drugs in the treatment of plaque psoriasis, PMID: 32192366
Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More, PMID: 32570252
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?, PMID: 31327402
IL-23 inhibitors for moderate-to-severe psoriasis, PMID: 30215632
Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment, PMID: 29796240
Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review, PMID: 32530083
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease, PMID: 30056776
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules, PMID: 34239295
Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis, PMID: 31447673
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review, PMID: 32427307
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis, PMID: 33871055
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges, PMID: 34079536
Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis, PMID: 32166932
For research use only. Not for human or drug use.
